Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150
Liver Cancer · 03.03.2025 · 14 (5) · 539-554
DOI: 10.1159/000544981 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 03.03.2025. Verfasst von Masatoshi Kudo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Introduction
IMbrave150 established first-line atezolizumab plus bevacizumab as a global standard of care for unresectable hepatocellular carcinoma (HCC). We report exploratory analyses of associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR).
Methods
IMbrave150 was a phase III randomized study of atezolizumab plus bevacizumab versus sorafenib in patients with unresectable HCC. DpR was defined as maximum tumor shrinkage from baseline based on the sum of longest diameters per independent review facility (IRF)-assessed RECIST 1.1. DoR was defined as time from first complete/partial response by IRF-assessed RECIST 1.1 until progression or death. Associations between OS and DpR or DoR were evaluated by scatterplot in both arms; OS and PFS were evaluated by DpR in atezolizumab plus bevacizumab-treated patients. To minimize immortal time bias, the DpR analysis included patients who survived ≥6 months.
Results
Of 312 and 140 patients with baseline measurable disease in the atezolizumab plus bevacizumab and sorafenib arms, respectively, 264 and 99 surviving ≥6 months were included in the DpR analysis, and 97 and 18 in the DoR analysis. Tumor shrinkage occurred in 230/312 (74%) patients in the atezolizumab plus bevacizumab arm and 76/140 (54%) in the sorafenib arm; their mean (SD) DpR was −42.5% (32.4%) and −25.0% (21.9%), respectively. Atezolizumab plus bevacizumab-treated ≥6-month survivors with DpR
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
- Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
- Department of Medicine, Division of Hematology and Oncology, Jonsson Comprehensive Cancer Center, Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
- Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany.
- Department of Medical Oncology, Gustave Roussy Cancer Center, Inserm U1279, Paris-Saclay University, Villejuif, France.
- Department of Oncology, National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan.
Förderung
- NCI NIH HHS
Zitieren
APA
Kudo, M., Yamashita, T., Finn, R. S., Galle, P. R., Ducreux, M., Cheng, A. L., Tsuchiya, K., Sakamoto, N., Hige, S., Take, R., Yamada, K., Nakagawa, Y., Takahashi, H., & Ikeda, M. (2025). Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150. Liver Cancer, 14(5), 539-554. https://doi.org/10.1159/000544981
Vancouver
Kudo M, Yamashita T, Finn RS, Galle PR, Ducreux M, Cheng AL, et al. Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150. Liver Cancer. 2025;14(5):539-554. doi:10.1159/000544981
BibTeX
@article{Kudo2025,
author = {Kudo, Masatoshi and Yamashita, Tatsuya and Finn, Richard S and Galle, Peter R and Ducreux, Michel and Cheng, Ann-Lii and Tsuchiya, Kaoru and Sakamoto, Naoya and Hige, Shuhei and Take, Ryosuke and Yamada, Kyoko and Nakagawa, Yuki and Takahashi, Hayato and Ikeda, Masafumi},
title = {Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150},
journal = {Liver Cancer},
year = {2025},
volume = {14},
number = {5},
pages = {539--554},
doi = {10.1159/000544981}
}
EUVIMED